Cargando…
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours
BACKGROUND: Ewing sarcoma/PNET is managed with treatment paradigms involving combinations of chemotherapy, surgery, and sometimes radiation. Although the 5-year survival rate of non-metastatic disease approaches 70%, those cases that are metastatic and those that recur have 5-year survival rates of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351706/ https://www.ncbi.nlm.nih.gov/pubmed/22587874 http://dx.doi.org/10.1186/2045-3329-2-6 |